US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Tevogen Bio Holdings

1.05

+0.0000

Volume:- -

Turnover:394.30K

Market Cap:193.09M

PE:-14.99

High:1.05

Open:1.05

Low:1.05

Close:1.05

Loading ...

Overview Company News Filings

Tevogen Bio CEO Reflects on Public Support, Reaffirms Preserving Shareholder Value Remains His Priority, and Reinforces Options Including a Potential Share Buyback to Support Company Value

THOMSON REUTERS

Press Release: Tevogen Bio CEO Reflects on Public Support, Reaffirms Preserving Shareholder Value Remains His Priority, and Reinforces Options Including a Potential Share Buyback to Support Company Value

Wall Street Set to Open Higher Wednesday as Investors Await Nvidia's Earnings, Jobless Data

MT Newswires Live

Tevogen Bio Surges Premarket After Reporting Q3 Results, 'Nearly All' Liabilities Eliminated

MT Newswires Live

Tevogen reports Q3 EPS (3c) vs (3c) last year

Tevogen Bio Holdings Q3 EPS $(0.03) Same As Prior Year

BRIEF-Tevogen Bio Reports Third Quarter 2024 Financial

Tevogen Bio Reports Third Quarter 2024 Financial Results; Highlights Significantly Improved Financial Position, Unreported Asset Value on Balance Sheets, Efficient Business Model

THOMSON REUTERS

Press Release: Tevogen Bio Reports Third Quarter 2024 Financial Results; Highlights Significantly Improved Financial Position, Unreported Asset Value on Balance Sheets, Efficient Business Model

Tevogen Bio Delays Latest Quarterly Filing with SEC

Tevogen Founder Reflects on Importance of Preserving Shareholder Value While Navigating Growth as it Prepares to File Quarterly Financials

Tevogen Bio Nears Finalization of Agreement to Enhance R&D and Manufacturing Capabilities; $36 Million Line of Credit Available for Continued Operations

THOMSON REUTERS

Tevogen Bio Nears Finalization of Agreement to Enhance R&D and Manufacturing Capabilities; $36 Million Line of Credit Available for Continued Operations

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/TVGN/news?page=4"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"TVGN","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"TVGN\",,,,,undefined,":{"symbol":"TVGN","market":"US","secType":"STK","nameCN":"Tevogen Bio Holdings","latestPrice":1.05,"timestamp":1746624600000,"preClose":1.05,"halted":0,"volume":0,"delay":0,"floatShares":22757419,"shares":183893433,"eps":-0.070045,"marketStatus":"Trading","change":0,"latestTime":"05-07 09:30:01 EDT","open":1.05,"high":1.05,"low":1.05,"amount":394299.03246019996,"amplitude":0,"askPrice":1.04,"askSize":200,"bidPrice":1.01,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-0.070045,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1746648000000},"marketStatusCode":2,"adr":0,"exchange":"NASDAQ","adjPreClose":1.05,"preHourTrading":{"tag":"盘前","latestPrice":1.0204,"preClose":1.05,"latestTime":"09:21 EDT","volume":8391,"amount":8510.7957897,"timestamp":1746624060135},"postHourTrading":{"tag":"盘后","latestPrice":1.05,"preClose":1.05,"latestTime":"19:58 EDT","volume":9452,"amount":9897.383,"timestamp":1746575925652},"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"TVGN\",,,,,undefined,":{"symbol":"TVGN","floatShares":22757419,"roa":"-746.67%","roe":"--","lyrEps":-0.070045,"shares":183893433,"dividePrice":0,"high":1.05,"amplitude":0,"preClose":1.05,"low":1.05,"week52Low":0.2556,"pbRate":"-12.48","week52High":3.09,"institutionHeld":0,"latestPrice":1.05,"committee":-0.333333,"eps":-0.070045,"divideRate":0,"volume":0,"delay":0,"ttmEps":-0.070045,"open":1.05,"prevYearClose":1.03,"prevWeekClose":1.01,"prevMonthClose":1.03,"prevQuarterClose":1.08,"fiveDayClose":1.03,"twentyDayClose":0.96,"sixtyDayClose":1.55},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"TVGN\",pageSize:20,pageCount:4,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2485428845","title":"Tevogen Bio CEO Reflects on Public Support, Reaffirms Preserving Shareholder Value Remains His Priority, and Reinforces Options Including a Potential Share Buyback to Support Company Value","url":"https://stock-news.laohu8.com/highlight/detail?id=2485428845","media":"THOMSON REUTERS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485428845?lang=en_us&edition=fundamental","pubTime":"2024-11-22 04:59","pubTimestamp":1732222783,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241121:nTUA1YPKL2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TVGN","TVGNW","BK4139"],"gpt_icon":0},{"id":"2485428639","title":"Press Release: Tevogen Bio CEO Reflects on Public Support, Reaffirms Preserving Shareholder Value Remains His Priority, and Reinforces Options Including a Potential Share Buyback to Support Company Value","url":"https://stock-news.laohu8.com/highlight/detail?id=2485428639","media":"Dow Jones","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485428639?lang=en_us&edition=fundamental","pubTime":"2024-11-22 04:59","pubTimestamp":1732222740,"startTime":"0","endTime":"0","summary":"Tevogen Bio CEO Reflects on Public Support, Reaffirms Preserving Shareholder Value Remains His Priority, and Reinforces Options Including a Potential Share Buyback to Support Company Value. WARREN, N.J., Nov. 21, 2024  -- Tevogen Bio  , a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified T cell therapeutics to treat infectious disease and cancers, today expresses gratitude to shareholders for their unwavering support and trust in Tevogen Bio and its leadership. The commitment fuels the company's determination to advance its mission of developing accessible, life-saving therapeutics.The company recently announced significant progress through its third quarter financial results for 2024, including, reduction of a net loss by $52.5 million, elimination of nearly all liabilities, and reiterating availability of sufficient capital to fund operations for the next 33 months.Tevogen is driven by a team of highly experienced industry leaders and dis","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","TVGN"],"gpt_icon":0},{"id":"2484114228","title":"Wall Street Set to Open Higher Wednesday as Investors Await Nvidia's Earnings, Jobless Data","url":"https://stock-news.laohu8.com/highlight/detail?id=2484114228","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484114228?lang=en_us&edition=fundamental","pubTime":"2024-11-20 22:11","pubTimestamp":1732111864,"startTime":"0","endTime":"0","summary":"US stocks look set to open higher in Wednesday's trading session as investors await Nvidia's (NVDA) earnings report and look ahead to key data coming out Thursday, including initial jobless claims, th","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ISBC","SKYT","HOFV","TVGN","TGT","AVNS","SOAR","NVDA",".SPX",".DJI","CARE","QSI",".IXIC","PKBK","KITT"],"gpt_icon":1},{"id":"2484619607","title":"Tevogen Bio Surges Premarket After Reporting Q3 Results, 'Nearly All' Liabilities Eliminated","url":"https://stock-news.laohu8.com/highlight/detail?id=2484619607","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484619607?lang=en_us&edition=fundamental","pubTime":"2024-11-20 19:13","pubTimestamp":1732101201,"startTime":"0","endTime":"0","summary":"Tevogen Bio Surges Premarket After Reporting Q3 Results, 'Nearly All' Liabilities Eliminated","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["TVGN","BK4139"],"gpt_icon":0},{"id":"2484901480","title":"Tevogen reports Q3 EPS (3c) vs (3c) last year","url":"https://stock-news.laohu8.com/highlight/detail?id=2484901480","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484901480?lang=en_us&edition=fundamental","pubTime":"2024-11-20 05:55","pubTimestamp":1732053309,"startTime":"0","endTime":"0","summary":"Kirti Desai, CPA, Tevogen’s (TVGN) CFO, commented, “The company is in a unique position as it relates to reporting intangible assets on our balance...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/tevogen-reports-q3-eps-3c-vs-3c-last-year?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/tevogen-reports-q3-eps-3c-vs-3c-last-year?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","TVGN"],"gpt_icon":0},{"id":"2484693909","title":"Tevogen Bio Holdings Q3 EPS $(0.03) Same As Prior Year","url":"https://stock-news.laohu8.com/highlight/detail?id=2484693909","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484693909?lang=en_us&edition=fundamental","pubTime":"2024-11-20 05:53","pubTimestamp":1732053208,"startTime":"0","endTime":"0","summary":"Tevogen Bio Holdings Q3 EPS $(0.03) Same As Prior Year","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/24/11/42076122/tevogen-bio-holdings-q3-eps-0-03-same-as-prior-year","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Tevogen Bio Holdings Q3 EPS $(0.03) Same As Prior Year","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TVGN"],"gpt_icon":0},{"id":"2484390961","title":"BRIEF-Tevogen Bio Reports Third Quarter 2024 Financial","url":"https://stock-news.laohu8.com/highlight/detail?id=2484390961","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484390961?lang=en_us&edition=fundamental","pubTime":"2024-11-20 05:52","pubTimestamp":1732053136,"startTime":"0","endTime":"0","summary":"BRIEF-Tevogen Bio Reports Third Quarter 2024 Financial Nov 19 (Reuters) - Tevogen Bio Holdings Inc TVGN.O:TEVOGEN BIO REPORTS THIRD QUARTER 2024 FINANCIAL RESULTS; HIGHLIGHTS SIGNIFICANTLY IMPROVED FI","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241119:nTUA4QZXGV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","TVGN","TVGNW"],"gpt_icon":0},{"id":"2484909633","title":"Tevogen Bio Reports Third Quarter 2024 Financial Results; Highlights Significantly Improved Financial Position, Unreported Asset Value on Balance Sheets, Efficient Business Model","url":"https://stock-news.laohu8.com/highlight/detail?id=2484909633","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484909633?lang=en_us&edition=fundamental","pubTime":"2024-11-20 05:50","pubTimestamp":1732053042,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241119:nTUA4QZXGV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TVGN","BK4139","TVGNW"],"gpt_icon":0},{"id":"2484909632","title":"Press Release: Tevogen Bio Reports Third Quarter 2024 Financial Results; Highlights Significantly Improved Financial Position, Unreported Asset Value on Balance Sheets, Efficient Business Model","url":"https://stock-news.laohu8.com/highlight/detail?id=2484909632","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484909632?lang=en_us&edition=fundamental","pubTime":"2024-11-20 05:50","pubTimestamp":1732053000,"startTime":"0","endTime":"0","summary":"Tevogen Bio Reports Third Quarter 2024 Financial Results; Highlights Significantly Improved Financial Position, Unreported Asset Value on Balance Sheets, Efficient Business Model. -- Improved operating performance by reducing net loss by $52.5 million;reported net loss of $4.3 million and $56.8 million for the nine months. its liabilities; reported $10.5 million as of September 30, 2024, and. Tevogen reiterated its confidence in its financial stability, confirming sufficient available capital to fund operations for at least the next 33 months, supported by a loan agreement, which Tevogen entered into in June. Additionally, Tevogen eliminated almost all of its liabilities which were $99.9 million as reported at December 31, 2023 and now are $10.5 million as reported at September 30, 2024.Kirti Desai, CPA, Tevogen's CFO, commented, \"The company is in a unique position as it relates to reporting intangible assets on our balance sheet. Tevogen has multiple granted patents, which were devel","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TVGN","BK4139"],"gpt_icon":0},{"id":"2483839531","title":"Tevogen Bio Delays Latest Quarterly Filing with SEC","url":"https://stock-news.laohu8.com/highlight/detail?id=2483839531","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483839531?lang=en_us&edition=fundamental","pubTime":"2024-11-16 06:26","pubTimestamp":1731709560,"startTime":"0","endTime":"0","summary":"Tevogen Bio said it is delaying the publication of its filing third-quarter filing with the Securities and Exchange Commission, citing material weaknesses in its internal controls over financial reporting.The biotechnology company on Friday said the delay follows a recent change in the third party firm in charge of a portion of its internal accounting and financing reporting.Overall for the third quarter, the company expects to post a loss of about $4.3 million for the first nine months of 2024, down from a loss of $56.8 million for the same period a year earlier.The news come a day after founder and Chief Executive Ryan Saadi suggested the company needed to raise capital.\"Founders must navigate the need for capital to fuel growth with a vigilant eye on avoiding equity dilution,\" Saadi said. \"Our financing options must consider preserving shareholder value and the potential equity dilution of warrant conversion at a strike price of $11.50 per share.\"","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","TVGN"],"gpt_icon":0},{"id":"2483337963","title":"Tevogen Founder Reflects on Importance of Preserving Shareholder Value While Navigating Growth as it Prepares to File Quarterly Financials","url":"https://stock-news.laohu8.com/highlight/detail?id=2483337963","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483337963?lang=en_us&edition=fundamental","pubTime":"2024-11-15 04:49","pubTimestamp":1731617340,"startTime":"0","endTime":"0","summary":"Since its founding in 2020, Tevogen Bio has developed a significant asset portfolio, and kept expenditures under $40 million, a fraction of the industry norm.In his conversation with the leadership team, Dr. Saadi shared, “Since its founding in 2020, Tevogen Bio has developed a significant asset portfolio, and kept expenditures under $40 million, a fraction of the industry norm. Tevogen’s success would not be possible without its passionate team united by a common vision.” He added, “Founders must navigate the need for capital to fuel growth with a vigilant eye on avoiding equity dilution. Our financing options must consider preserving shareholder value and the potential equity dilution of warrant conversion at a strike price of $11.50 per share.”Tevogen is a clinical-stage specialty immunotherapy company harnessing one of nature’s most powerful immunological weapons, CD8+ cytotoxic T lymphocytes, to develop off-the-shelf, genetically unmodified precision T cell therapies for the treat","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/BJRd_xndXodq.4BrmsL4bg--~B/aD02Mjg7dz0xMjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/927ad684614f9ce891b7a2e4313e2d86","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/BJRd_xndXodq.4BrmsL4bg--~B/aD02Mjg7dz0xMjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/927ad684614f9ce891b7a2e4313e2d86"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/tevogen-founder-reflects-importance-preserving-204900794.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","TVGNW","TVGN"],"gpt_icon":1},{"id":"2482645853","title":"Tevogen Bio Nears Finalization of Agreement to Enhance R&D and Manufacturing Capabilities; $36 Million Line of Credit Available for Continued Operations","url":"https://stock-news.laohu8.com/highlight/detail?id=2482645853","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482645853?lang=en_us&edition=fundamental","pubTime":"2024-11-09 04:36","pubTimestamp":1731098208,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241108:nTUA5FVRKZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TVGNW","TVGN","BK4139"],"gpt_icon":0},{"id":"2482458288","title":"Tevogen Bio Nears Finalization of Agreement to Enhance R&D and Manufacturing Capabilities; $36 Million Line of Credit Available for Continued Operations","url":"https://stock-news.laohu8.com/highlight/detail?id=2482458288","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482458288?lang=en_us&edition=fundamental","pubTime":"2024-11-09 04:36","pubTimestamp":1731098160,"startTime":"0","endTime":"0","summary":"WARREN, N.J., Nov. 08, 2024  -- Tevogen Bio  , a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified T cell therapeutics to treat infectious disease and cancers, nears finalization of agreement with CD8 Technology for a turn-key facility intended to support both pre-clinical research and GMP manufacturing capabilities, staffed by Tevogen.In tandem with this announcement, Tevogen Bio reaffirms its existing agreement which provides access to a $36 million line of credit to ensure ongoing operations and fuel future growth.Tevogen is driven by a team of highly experienced industry leaders and distinguished scientists with drug development and global product launch experience. Tevogen’s leadership believes that accessible personalized therapeutics are the next frontier of medicine, and that disruptive business models are required to susta","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/BJRd_xndXodq.4BrmsL4bg--~B/aD02Mjg7dz0xMjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/927ad684614f9ce891b7a2e4313e2d86","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/BJRd_xndXodq.4BrmsL4bg--~B/aD02Mjg7dz0xMjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/927ad684614f9ce891b7a2e4313e2d86"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/tevogen-bio-nears-finalization-agreement-203600118.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["TVGNW","BK4139","TVGN"],"gpt_icon":1}],"pageSize":20,"totalPage":4,"pageCount":4,"totalSize":73,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/TVGN\",params:#limit:5,,,undefined,":[{"market":"US","date":"2024-02-15","symbol":"TVGN","reason":null,"defaultRemindTime":1708007400000,"announcedDate":"2024-02-14","type":"delisting","dateTimestamp":1707973200000}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"TVGN\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"TVGN\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":1,"updateTime":1741752000000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/TVGN\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"TVGN","date":"2025-05-06","current":-14.199872,"percent":0.604982,"low":-87.683882,"twenty":-32.729588,"median":-21.570546,"eighty":-7.830197,"high":-2.106753,"avg":-22.803515,"sd":16.095128,"marketCap":194927038},"quantilePoints":[{"date":"2024-03-01","current":-58.029616,"twenty":-57.969868,"median":-57.58151,"eighty":-55.109463,"marketCap":1279054027},{"date":"2024-03-08","current":-55.116932,"twenty":-57.969868,"median":-57.3948,"eighty":-55.049716,"marketCap":1214854404},{"date":"2024-03-15","current":-48.544723,"twenty":-57.715942,"median":-55.116932,"eighty":-49.664986,"marketCap":1069993717},{"date":"2024-03-22","current":-31.890149,"twenty":-57.596447,"median":-52.465643,"eighty":-44.108482,"marketCap":702903564},{"date":"2024-03-28","current":-25.919148,"twenty":-57.357457,"median":-49.38492,"eighty":-32.983824,"marketCap":571294337},{"date":"2024-04-05","current":-25.392625,"twenty":-55.998205,"median":-48.543977,"eighty":-28.607629,"marketCap":559689021},{"date":"2024-04-12","current":-18.446995,"twenty":-55.146806,"median":-35.064227,"eighty":-23.267262,"marketCap":406597612},{"date":"2024-04-19","current":-15.833048,"twenty":-54.915285,"median":-32.71989,"eighty":-19.118705,"marketCap":348982566},{"date":"2024-04-26","current":-6.348156,"twenty":-53.503754,"median":-29.329228,"eighty":-17.595595,"marketCap":139922255},{"date":"2024-05-03","current":-7.365355,"twenty":-52.428301,"median":-25.919148,"eighty":-15.026459,"marketCap":162342739},{"date":"2024-05-10","current":-2.698495,"twenty":-50.822591,"median":-23.061357,"eighty":-9.708944,"marketCap":163198734},{"date":"2024-05-17","current":-2.422494,"twenty":-49.291565,"median":-20.164731,"eighty":-7.316959,"marketCap":146506832},{"date":"2024-05-24","current":-2.231961,"twenty":-48.694091,"median":-18.372311,"eighty":-2.71254,"marketCap":134983822},{"date":"2024-05-31","current":-2.106753,"twenty":-48.544425,"median":-17.961548,"eighty":-2.656034,"marketCap":127411559},{"date":"2024-06-07","current":-8.033143,"twenty":-47.558444,"median":-17.550785,"eighty":-2.656034,"marketCap":148265257},{"date":"2024-06-14","current":-7.903098,"twenty":-44.108482,"median":-15.833048,"eighty":-2.68298,"marketCap":145865070},{"date":"2024-06-21","current":-6.795171,"twenty":-36.221832,"median":-12.47226,"eighty":-2.696046,"marketCap":125416385},{"date":"2024-06-28","current":-6.570165,"twenty":-35.295748,"median":-12.322891,"eighty":-2.697026,"marketCap":121263525},{"date":"2024-07-05","current":-6.173255,"twenty":-33.757254,"median":-8.033143,"eighty":-2.703177,"marketCap":113937879},{"date":"2024-07-12","current":-6.299258,"twenty":-33.071802,"median":-7.830197,"eighty":-2.721904,"marketCap":116263481},{"date":"2024-07-15","current":-6.435162,"twenty":-32.983824,"median":-7.830197,"eighty":-2.721904,"marketCap":118771808},{"date":"2024-08-02","current":-5.57114,"twenty":-32.895846,"median":-7.830197,"eighty":-2.721904,"marketCap":102824824},{"date":"2024-08-09","current":-5.526139,"twenty":-32.222045,"median":-7.468419,"eighty":-3.563104,"marketCap":101994252},{"date":"2024-08-16","current":-20.612899,"twenty":-30.545833,"median":-7.468046,"eighty":-4.127144,"marketCap":122353801},{"date":"2024-08-23","current":-17.275162,"twenty":-29.265149,"median":-7.830197,"eighty":-4.681198,"marketCap":102541700},{"date":"2024-08-30","current":-14.308285,"twenty":-28.407028,"median":-7.866648,"eighty":-5.281333,"marketCap":84930944},{"date":"2024-09-06","current":-12.936966,"twenty":-27.171154,"median":-9.617885,"eighty":-5.454137,"marketCap":76791088},{"date":"2024-09-13","current":-14.230663,"twenty":-25.708539,"median":-12.097501,"eighty":-5.499138,"marketCap":84470197},{"date":"2024-09-20","current":-12.649478,"twenty":-24.871927,"median":-12.454498,"eighty":-5.544139,"marketCap":75084620},{"date":"2024-09-27","current":-11.784139,"twenty":-23.267262,"median":-12.36199,"eighty":-5.658262,"marketCap":69948149},{"date":"2024-10-04","current":-8.756889,"twenty":-21.942215,"median":-12.240382,"eighty":-5.887588,"marketCap":51979034},{"date":"2024-10-11","current":-9.208245,"twenty":-21.329829,"median":-12.040003,"eighty":-6.069393,"marketCap":54658190},{"date":"2024-10-18","current":-39.673363,"twenty":-24.871927,"median":-12.127687,"eighty":-6.141394,"marketCap":235492672},{"date":"2024-10-25","current":-73.596963,"twenty":-29.393307,"median":-12.327491,"eighty":-6.173255,"marketCap":436855971},{"date":"2024-10-31","current":-70.722082,"twenty":-31.779361,"median":-12.436737,"eighty":-6.180635,"marketCap":419791285},{"date":"2024-11-08","current":-32.773648,"twenty":-33.757254,"median":-12.633666,"eighty":-6.224556,"marketCap":194537424},{"date":"2024-11-15","current":-42.548244,"twenty":-38.983392,"median":-12.936966,"eighty":-6.285578,"marketCap":252557358},{"date":"2024-11-22","current":-36.270609,"twenty":-39.155884,"median":-13.187081,"eighty":-6.299438,"marketCap":287084045},{"date":"2024-11-29","current":-28.972255,"twenty":-38.235922,"median":-13.602501,"eighty":-6.300158,"marketCap":229317133},{"date":"2024-12-06","current":-23.222036,"twenty":-37.373458,"median":-13.816575,"eighty":-6.348156,"marketCap":183803809},{"date":"2024-12-13","current":-22.337387,"twenty":-36.270609,"median":-14.269474,"eighty":-6.435162,"marketCap":176801759},{"date":"2024-12-20","current":-21.33331,"twenty":-36.221832,"median":-15.004006,"eighty":-6.508963,"marketCap":168854432},{"date":"2024-12-27","current":-23.222036,"twenty":-35.303209,"median":-15.833048,"eighty":-6.557925,"marketCap":183803809},{"date":"2025-01-03","current":-23.443198,"twenty":-34.373394,"median":-17.065337,"eighty":-6.580965,"marketCap":185554321},{"date":"2025-01-10","current":-28.52993,"twenty":-33.790638,"median":-17.550785,"eighty":-6.670967,"marketCap":225816108},{"date":"2025-01-17","current":-26.760632,"twenty":-33.439732,"median":-17.684618,"eighty":-6.873653,"marketCap":211812008},{"date":"2025-01-24","current":-30.52039,"twenty":-33.171426,"median":-18.032197,"eighty":-7.005548,"marketCap":241570720},{"date":"2025-01-31","current":-29.635741,"twenty":-33.528197,"median":-18.446995,"eighty":-7.075423,"marketCap":234568670},{"date":"2025-02-07","current":-31.405039,"twenty":-33.171426,"median":-19.295444,"eighty":-7.138439,"marketCap":248572770},{"date":"2025-02-14","current":-34.501311,"twenty":-33.892862,"median":-20.164731,"eighty":-7.192457,"marketCap":273079945},{"date":"2025-02-21","current":-34.280148,"twenty":-34.280148,"median":-20.612899,"eighty":-7.244366,"marketCap":271329432},{"date":"2025-02-28","current":-27.645281,"twenty":-34.280148,"median":-21.570546,"eighty":-7.365355,"marketCap":218814058},{"date":"2025-03-07","current":-24.327847,"twenty":-34.058986,"median":-22.031836,"eighty":-7.370735,"marketCap":192556371},{"date":"2025-03-14","current":-24.54901,"twenty":-33.906622,"median":-22.226806,"eighty":-7.443187,"marketCap":194306884},{"date":"2025-03-21","current":-25.875983,"twenty":-33.837824,"median":-22.558549,"eighty":-7.452187,"marketCap":204809958},{"date":"2025-03-28","current":-26.53947,"twenty":-33.616662,"median":-23.000874,"eighty":-7.454567,"marketCap":210061496},{"date":"2025-04-04","current":-13.396106,"twenty":-33.174337,"median":-23.222036,"eighty":-7.467672,"marketCap":183893433},{"date":"2025-04-11","current":-13.396106,"twenty":-33.15978,"median":-22.669131,"eighty":-7.468419,"marketCap":183893433},{"date":"2025-04-17","current":-13.664028,"twenty":-32.994496,"median":-22.447968,"eighty":-7.468419,"marketCap":187571301},{"date":"2025-04-25","current":-13.530067,"twenty":-32.809553,"median":-22.063146,"eighty":-7.757841,"marketCap":185732367},{"date":"2025-05-02","current":-13.10675,"twenty":-32.74034,"median":-21.917772,"eighty":-7.830197,"marketCap":179921334},{"date":"2025-05-06","current":-14.199872,"twenty":-32.729588,"median":-21.570546,"eighty":-7.830197,"marketCap":194927038}],"updateTime":1746624601197}}}